RES 420

Drug Profile

RES 420

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator PharmaMax
  • Class Antivirals
  • Mechanism of Action Viral protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Viral infections

Most Recent Events

  • 01 Aug 2016 Clinical trials in Viral infections in China (Intranasal) before August 2016
  • 01 Aug 2016 PharmaMax has patent protection for RES 420 in China before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top